|
1. Burns A, Zaudig M. Mild cognitive impairment in older people. Lancet 2002; 360: 1963-1965.
2. Parnetti L et al. Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data. Mech Ageing Dev 2001 Nov; 122(16): 2041-2055.
3. Klegeris A, McGeer P. Cyclooxygenase and 5-lipooxygenase inhibitors protect against mononuclear phagocyte neurotoxicity. Neurobiol Aging 2002; 23: 787-794.
4. Life Extension magazine, May 2001 pg.11., The Silent Stroke Epidemic.
5. Paris D, et al. AB vasoactivity: an inflammatory reaction. Ann NY Acad Sci 2000, Apr; 903: 97-109.
6. Bartus RT, et al. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408-414.
7. Ritchie K, et al. Is senile dementia age- related or ageing-related? – evidence from a meta-analysis of dementia prevalence in the oldest old. Lancet 1995; 346: 931-934.
8. Ritchie K, Lovestone S. The dementias. Lancet 2002; 360: 1759-1766.
9. Hofman A, et al. The prevalence of dementia in Europe: a collaborative study of 1980-1990 findings. Int J Epidemiol 1991; 20: 736-748.
10. Jorm AF, et al. The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand 1987; 76: 465-479.
11. Scali C, et al. The selective cyclooxygenase-2 inhibitor rofecoxib suppresses brain inflammation and protects cholinergic neurons from excitotoxic degeneration in vivo. Neuroscience 2003;117: 909-919.
12. Teismann P, et al. Cyclooxygenase-2 is instrumental in Parkinson’s disease neurodegeneration. PNAS 2003; 100 (9):5473-5478.
13. Pompl PN, et al. A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. FASEB J. 2003; Apr;17(6):725-7.
14. Dennis and Company Research. Nexrutine® human trial report. Next Pharmaceuticals, Inc. 2002; 13.
15. Manev H, et al. Putative role of neuronal 5-lipoxygenase in an aging brain. FASEB J 2000; Jul;14(10):1464-9.
16. Pignatelli P, et al. The flavonoids quercetin and catechin synergistically inhibit platelet function by antagonizing the intracellular production of hydrogen peroxide. Am J Clin Nutr 2000; 72: 1150-1155.
17. Yamamoto K, et al. Plasminogen activator inhibitor-1 is a major stress- regulated gene: Implications for stress- induced thrombosis in aged individuals. Proc Natl Acad Sci 2002; 99 (2): 890-895.
18. Breteler M. Vascular involvement in cognitive decline and dementia: Epidemiologic evidence from the Rotterdam study and the Rotterdam scan study. Ann N Y Acad Sci 2000, Apr;903:457-465.
19. Iadecola C, Gorelick P.B. Converging pathogenic mechanisms in vascular and neurodegenerative dementia. Stroke 2003; 34: 335-337.
20. Schreiber S, et al. An open trial of plant- source derived Phosphatidylserine for the treatment of age-related cognitive decline. Isr J Psychiatry Relat Sci 2000; 37 (4): 302-307.
21. Palmieri G, et al. Double-blind controlled trial of phosphatidylserine in patients with senile mental deterioration. Clin Trials J 1987; 24:73-83.
22. Delwaide PJ, et al. Double-blind randomized controlled study of phosphatidylserine in senile demented patients. Acta Neurol Scand 1986; 73(2):136-40.
23. Fungfeld EW, et al. Double-blind study with Phosphatidylserine (PS) in parkinsonian patients with senile dementia of Alzheimer’s type (SDAT). Prog Clin Biol Res 1989;317: 1235-1246.
24. Van den Besselaar AM. Phosphatidylethanolamine and Phosphatidylserine synergistically promote heparin’s anticoagulant effect. Blood Coagul Fibrinolysis 1995; 6: 239-244.
25. Vas A, et al. Clinical and non-clinical investigations using positron emission tomography, near-infrared spectroscopy and transcranial Doppler methods on the neuroprotective drug vinpocetine: A summary of evidences. J Neurol Sci 2002; 203-204: 259-262.
26. Laszy J, Gyertyan I. Comparison of cognitive enhancer activity of acetylcholinesterase inhibitors and vinpocetine. Neurobiology of Aging; 2002 Jul-Aug, Suppl 1; 23(1):357. |